Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Nov;82(2):284–288. doi: 10.1111/j.1365-2249.1990.tb05440.x

Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin.

J A Aarli 1, K Stefansson 1, L S Marton 1, R L Wollmann 1
PMCID: PMC1535140  PMID: 2242609

Abstract

Patients with myasthenia gravis (MG) and thymoma have in their sera antibodies which react with non-receptor antigens from striated muscle. The purpose of this investigation was to characterize the antigen(s). Polypeptides in homogenates from rat skeletal muscle were separated by SDS-PAGE and trans-blotted to nitrocellulose. Sera from six patients with MG and thymoma stained a large (molecular weight greater than 500 kD) polypeptide, while no staining was observed with sera from 20 non-thymoma MG patients. Titin is one of the large (greater than 500 kD) polypeptides of striated muscle and the antibody containing MG sera have antibodies that bind to titin in a preparation of myofibrillary proteins from rabbit skeletal muscle. The staining pattern is identical to that obtained with antiserum to titin, showing that the antigen has the same electrophoretic mobility as titin. Antibodies from the sera of the patients with MG and thymoma, affinity-purified on the large polypeptide, reacted with skeletal muscle sections in a cross-striational pattern, near the A/I band junction but within the I band, corresponding to the localization of one of the epitopes of titin. Our findings therefore indicate that the muscle antibodies found in the sera from some MG patients with thymoma are directed against titin.

Full text

PDF
284

Images in this article

286Fig. 1
on p.286
286Fig. 2
on p.286
287Fig. 3
on p.287

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarli J. A., Gilhus N. E., Hofstad H. CA-antibody: an immunological marker of thymic neoplasia in myasthenia gravis? Acta Neurol Scand. 1987 Jul;76(1):55–57. doi: 10.1111/j.1600-0404.1987.tb03544.x. [DOI] [PubMed] [Google Scholar]
  2. Aarli J. A., Lefvert A. K., Tönder O. Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination. J Neuroimmunol. 1981 Dec;1(4):421–427. doi: 10.1016/0165-5728(81)90021-7. [DOI] [PubMed] [Google Scholar]
  3. BEUTNER E. H., WITEBSKY E., RICKEN D., ADLER R. H. Studies on autoantibodies in myasthenia gravis. JAMA. 1962 Oct 6;182:46–58. [PubMed] [Google Scholar]
  4. Drachman D. B., Adams R. N., Stanley E. F., Pestronk A. Mechanisms of acetylcholine receptor loss in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1980 Jul;43(7):601–610. doi: 10.1136/jnnp.43.7.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fürst D. O., Nave R., Osborn M., Weber K. Repetitive titin epitopes with a 42 nm spacing coincide in relative position with known A band striations also identified by major myosin-associated proteins. An immunoelectron-microscopical study on myofibrils. J Cell Sci. 1989 Sep;94(Pt 1):119–125. doi: 10.1242/jcs.94.1.119. [DOI] [PubMed] [Google Scholar]
  6. Fürst D. O., Osborn M., Nave R., Weber K. The organization of titin filaments in the half-sarcomere revealed by monoclonal antibodies in immunoelectron microscopy: a map of ten nonrepetitive epitopes starting at the Z line extends close to the M line. J Cell Biol. 1988 May;106(5):1563–1572. doi: 10.1083/jcb.106.5.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gilhus N. E., Aarli J. A., Christensson B., Matre R. Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymomas from myasthenia gravis patients. J Neuroimmunol. 1984 Nov;7(1):55–64. doi: 10.1016/s0165-5728(84)80006-5. [DOI] [PubMed] [Google Scholar]
  8. Hofstad H., Ohm O. J., Mørk S. J., Aarli J. A. Heart disease in myasthenia gravis. Acta Neurol Scand. 1984 Sep;70(3):176–184. doi: 10.1111/j.1600-0404.1984.tb00817.x. [DOI] [PubMed] [Google Scholar]
  9. Labeit S., Barlow D. P., Gautel M., Gibson T., Holt J., Hsieh C. L., Francke U., Leonard K., Wardale J., Whiting A. A regular pattern of two types of 100-residue motif in the sequence of titin. Nature. 1990 May 17;345(6272):273–276. doi: 10.1038/345273a0. [DOI] [PubMed] [Google Scholar]
  10. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  11. Lefvert A. K., Bergström K., Matell G., Osterman P. O., Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry. 1978 May;41(5):394–403. doi: 10.1136/jnnp.41.5.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Matsumura K., Shimizu T., Mannen T., Maruyama K. The immunological homology between two filamentous cross-linker phosphoproteins, connectin and cross-bridge region of neurofilament-H, is not affected by the phosphorylation state. J Biochem. 1989 Feb;105(2):226–230. doi: 10.1093/oxfordjournals.jbchem.a122643. [DOI] [PubMed] [Google Scholar]
  13. NASTUK W. L., PLESCIA O. J., OSSERMAN K. E. Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med. 1960 Oct;105:177–184. doi: 10.3181/00379727-105-26050. [DOI] [PubMed] [Google Scholar]
  14. Peers J., McDonald B. L., Dawkins R. L. The reactivity of the antistriational antibodies associated with thymoma and myasthenia gravis. Clin Exp Immunol. 1977 Jan;27(1):66–73. [PMC free article] [PubMed] [Google Scholar]
  15. Penn A. S., Schotland D. L., Lamme S. Antimuscle and antiacetylcholine receptor antibodies in myasthenia gravis. Muscle Nerve. 1986 Jun;9(5):407–415. doi: 10.1002/mus.880090505. [DOI] [PubMed] [Google Scholar]
  16. Strauss A. J., Kemp P. G., Jr Serum autoantibodies in myasthenia gravis and thymoma: selective affinity for I-bands of striated muscle as a guide to identification of antigen(s). J Immunol. 1967 Nov;99(5):945–953. [PubMed] [Google Scholar]
  17. Strauss A. J., van der Geld H. W., Kemp P. G., Jr, Exum E. D., Goodman H. C. Immunological concomitants of myasthenia gravis. Ann N Y Acad Sci. 1965 Jun 30;124(2):744–766. doi: 10.1111/j.1749-6632.1965.tb18999.x. [DOI] [PubMed] [Google Scholar]
  18. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vetters J. M. Immunofluorescence staining patterns in skeletal muscle using serum of myasthenic patients and normal controls. Immunology. 1965 Jul;9(1):93–95. [PMC free article] [PubMed] [Google Scholar]
  20. Vetters J. M. Muscle antibodies in myasthenia gravis. Immunology. 1967 Sep;13(3):275–280. [PMC free article] [PubMed] [Google Scholar]
  21. Wang K. Purification of titin and nebulin. Methods Enzymol. 1982;85(Pt B):264–274. doi: 10.1016/0076-6879(82)85025-8. [DOI] [PubMed] [Google Scholar]
  22. Wang K., Ramirez-Mitchell R., Palter D. Titin is an extraordinarily long, flexible, and slender myofibrillar protein. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3685–3689. doi: 10.1073/pnas.81.12.3685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Williams C. L., Lennon V. A. Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. J Exp Med. 1986 Oct 1;164(4):1043–1059. doi: 10.1084/jem.164.4.1043. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES